Kodiak Sciences (KOD) Stock Analysis & Winston Score

Kodiak Sciences is a clinical-stage biotechnology company focused on developing treatments for serious eye diseases. Its main program is tarcocimab tedromer, a drug designed to treat conditions like wet age-related macular degeneration (AMD) and diabetic retinopathy — diseases that can cause blindness in millions of people. The company's core technology, called ABC Platform, is meant to help drugs last longer in the eye so patients need fewer injections. Kodiak does not yet sell any approved products, so it currently earns no revenue — its 0% margins reflect a company still in research and development. It is based in Palo Alto, California, and operates primarily in the United States, though clinical trials span multiple countries. The eye disease market is large and competitive, with established players like Regeneron and Roche already selling treatments. Kodiak's main growth driver is winning regulatory approval for tarcocimab, but repeated clinical setbacks in recent years have raised significant questions about whether the drug will ultimately succeed.